Author Guidelines

1.1 Summary

Radcliffe's journals endeavour to publish unbiased content. All articles must be of an impartial nature.

Invited contributors are assessed by the editors-in-chief with the support of the section editors, and guidance from the editorial boards. Following acceptance of an invitation, the authors and journal managing editor, in conjunction with the editor-in-chief, formalise the working title and scope of the article.

We consider uninvited submissions provided they meet our publication criteria.

Following submission, articles are subject to independent double-blind peer review and copy-editing prior to publication. All articles must receive final approval of the editor-in-chief and/or section editors before they are published.

Articles must be submitted using our electronic peer review system, Editorial Manager. Please select the relevant journal below to submit a paper:

Arrhythmia and Electrophysiology Review (AER)

Cardiac Failure Review (CFR)

European Cardiology Review (ECR)

Interventional Cardiology: Reviews, Research, Resources (ICR³)

Journal of Asian Pacific Society Review (JAPSC)

US Cardiology Review (USC)

Vascular and Endovascular Review (VER)

If you have any editorial queries, please email the editorial contact for the relevant journal: ashlynne.merrifield@radcliffe-group.com for AER, ECR and JAPSC, agnieszka.topolska@radcliffe-group.com for CFR, ICR3, and VER and mirjam.boros@radcliffe-group.com for USC.

1.2 Benefits of Publishing with Us

Radcliffe Cardiology’s journals aim to support the continuous medical education of both specialist and general cardiologists. We publish balanced and comprehensive review articles written by leading authorities, addressing the most pertinent developments in their field. Our authors benefit from:

 

Open research

 

All research published in our portfolio of journals is open access which means the version of record (VOR) is freely accessible to everyone across the globe immediately upon publication. As an author you retain all non-commercial rights for articles published under the Creative Commons Attribution Non-commercial CC-BY-NC 4.0 license, allowing users to read, download, copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.

 

Quality

 

We are committed to the highest standards of peer review. All of our journals follow a rigorous double-blind peer review process that is conducted independently and treated confidentially. All articles and the peer review comments received are evaluated by the Editor-in-Chief before they make their decision.

 

Speed

 

On average, articles submitted to our journals receive their first decision in 5 weeks of submission, ensuring rapid review whilst maintaining high quality, rigorous peer review.

 

Visibility

 

In order to maximise the reach and impact of your research, we are committed to ensuring every article we publish is promoted as widely as possible. Along with open access, which supports increased readership and citations with no barriers to access, our marketing team with their SEO expertise, will ensure your research is visible to the widest possible audience, including marketing through our social and email channels to our global community of 100,000+ registered recipients.

 

Society Partnerships

 

We regularly collaborate with some of the leading societies and associations within the cardiology and vascular communities across our initiatives and activities. Within our journals portfolio, Arrhythmia & Electrophysiology Review is the official journal of the British Heart Rhythm Society (BHRS), European Cardiology Review has an official partnership with the International Society of Cardiovascular Pharmacotherapy (ISCP) and The Journal of Asian Pacific Society of Cardiology is the official journal of the Asian Pacific Society of Cardiology. Radcliffe Cardiology publishes the journal on behalf of the society.

 

Indexing

 

In addition to being available through our journal websites, your research will also be available through other major full-text repositories, with journals indexed in the following repositories:

 

Arrhythmia & Electrophysiology Review: PubMed, PubMed Central, Crossref, Emerging Sources Citation Index (ESCI), Scopus, ProQuest and the Directory of Open Access Journals (DOAJ)

Cardiac Failure Review: PubMed, PubMed Central, Crossref, Scopus and the Directory of Open Access Journals (DOAJ)

European Cardiology Review: PubMed, PubMed Central, Crossref, Emerging Sources Citation Index (ESCI), Scopus, and the Directory of Open Access Journals (DOAJ)

Interventional Cardiology Review3: PubMed, PubMed Central, Crossref, Scopus, and the Directory of Open Access Journals (DOAJ)

US Cardiology Review: Scopus and the Directory of Open Access Journals (DOAJ)

Vascular & Endovascular Review: Scopus and the Directory of Open Access Journals (DOAJ)

 

If you are interested in submitting an article, please visit the journals Author Guidelines page for more information.

 

1.3 Authorship Criteria

All authors involved should be listed and are accountable for the content should it be published and must meet the following conditions to be considered an author:

  1. Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; and
  2. Drafting the work or revising it critically for important intellectual content; and
  3. Final approval of the version to be published; and
  4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Those meeting the above criteria are eligible to participate in reviewing and drafting the final manuscript. The corresponding author will be responsible for key communication with the publisher. Those not meeting the above criteria should be acknowledged as a contributor in the acknowledgments section rather than an author. The editor is not held responsible for identifying authors on the manuscript. This information must be supplied at submission.

1.4 Submission Types

Articles accepted for publication include the following content types and may be solicited or unsolicited:

Content Type

Description

Keywords

Word limits (excluding references/abstract)

Misc.

Figs

Tables

Videos

Clinical perspectives

Accepted in journals?

Case report

Present novel findings or strategies on a particular topic to aid diagnosis/treatment/management

7

1500 – 3000

Max. 50 refs

Abstract to be supplied (120-160 words)

AER, VER

300dpi

Max. 5

tif,.pdf or .jpeg format

Editorial

*by invitation only

An article that reflects on a particular issue, event, methodology, innovation or gap in literature.

7

1500 – 2000

Max. 15 refs

Not subject to peer-review

 

 

All Journals

300dpi

Max. 5

tif,.pdf or .jpeg format

Expert opinion

Coverage of topical issues in cardiology from expert in field that will be of interest to readers

7

1500 – 2500

Max. 20 refs

Accompanied by an abstract (120-160 words)

All Journals

300dpi

Max. 5

tif,.pdf or .jpeg format

Letter to editor

Readers are invited to provide comment on articles for the EiC to read/respond.

7

1500

Max. 10 refs

Not subject to peer-review

All Journals

Review article

Summary and critical evaluation of current research in field and impact on current and future practice.

7

2500 – 5000

Max. 80 refs

Accompanied by an abstract (120-160 words)

Required in  AER, optional for others

All Journals

300dpi

Max. 5

tif,.pdf or .jpeg

Original

Research

Including clinical research, meta-analyses and translational science

7

2500 – 5000

Max. 100 refs

Accompanied by a structured abstract

(max 250 words)

Required 

CFR, ECR, ICR, USC

300dpi

Max. 5

tif,.pdf or .jpeg

1.5 Article Preparation: Checklist Summary

Section

Requirement

Submission types

  • Case Reports: 1,500 3,000 words excl abstract & refs. Max. 50 references.

  • Editorial: 1500-2000 words excl abstract & refs. Max. 15 references. Editorials are by invitation only. 

  • Expert Opinion: 1,500 – 2500 words excl abstract & ref. Max. 20 references

  • Letter: 1500 words. Max 10 references.

  • Review Article: 2,500 – 5,000 words excl abstract & ref. Max. 80 references.

  • Original Research: 2,500 – 5,000 words excl abstract & Ref. Max 100 references.

Manuscript

  • Submitted as word document
  • Continuous line numbering
  • Double spacing
  • Page numbers.

Title page

Title: of the article (<300 characters);

Short title (<75 characters);

Author(s) information: full name, position, institution and/or organisation, full contact information: email addresses for all authors and a postal correspondence address for the lead author. We also encourage ORCID identification to be listed.

Disclaimers: a statement of disclosure/conflicts of interest relevant to the article for each author; form for Disclosure of Potential Conflicts of Interest: www.icmje.org/conflicts-of-interest

Support statements: include grants, equipment, drugs, and /or other support that facilitated conduct of the work

Keywords: a maximum of 7 keywords to be listed

Word count: should be provided for the article and should not include the abstract

Abstract

Reviews, Expert Opinions and Case Reports:

Unstructured, unreferenced. Provides the context of the article. Should summarise the purpose, basic procedure, main findings and key conclusions.

<160 words

Original Research:

Structured including the following headings:

  • Background
  • Methods
  • Results
  • Conclusion
  • Trial Registration

The abstract should present essential data in 5 paragraphs. Use complete sentences. All data in the abstract also must appear in the manuscript text or tables.

< 250 words

Keywords

7

Clinical perspective

Summarising the clinical implications of your review in three to five bullet points.

Acknowledgements

The author(s) should acknowledge substantive contributions to the article, including assistance, advice, materials and other resources.

Conflicts of interest/disclosures

The author(s) should state any conflicts of interest/intellectual property to the article, including any sources of financial support or assistance for work; ensure sponsor names/sponsoring organizations are included and the for-profit interest(s) the sponsor represents, if applicable.

Ensure to highlight if authors had access to the study data.

We make it clear when any research has been funded. If a funded paper, please include the statement: Authors had full access to all data in this study and take full responsibility for the integrity of the data and the accuracy of the data analysis.

Informed consent

Authors should include a statement in the manuscript that informed consent was obtained, if experimentation with human subjects was conducted. The privacy rights of human subjects must always be observed. 

Declaration of Helsinki

The authors should state that their study complies with the Declaration of Helsinki, that the locally appointed ethics committee has approved the research protocol and that informed consent has been obtained from the subjects (or their legally authorised representative). 

Data Availability Statement

Include a data availability statement (DAS) that links to your data. Where the data cannot be shared, you should confirm why it is not possible to share the data within this statement. Please see Section 4.10 for full details of our Data Sharing Policy.

Layout

Reviews, Expert Opinions and Case Reports:

Divide the text under headings and subheadings. Keep these short and succinct (max 5 words) and similar in sense and style.

Original Research:

Must include the following headed sections:

  • Introduction
  • Methods
    • Patient and Public Involvement statement (if relevant)
  • Results
  • Discussion
    • Study limitations
  • Data Availability Statement

Language

All articles should be written in UK English, free from jargon, and the writing should be clear and direct. [note: USC Journal uses US English].

All acronyms and abbreviations must be explained in full at first mention.

Figures, tables, illustrations, screenshots and photographs

A maximum of five may be included. Anything over this amount should be supplied as supplementary data. In addition, any Tables that require more than 2 pages, must be supplied as supplementary material.

Figures must be supplied as digital files only (.tiff, .pdf or .jpeg files) and be at least 300 dpi.

Clear and concise titles/captions must be provided, and all symbols and abbreviations used must be defined in a footnote.

All figures must be referred to in the main text.

Figure and table legends must be included in the manuscript after the reference section

All abbreviations in figures must be spelled out in full in the figure caption.

High-resolution images to be provided at revision stages if not supplied at submission.

Tables:

Graphs and tables must be supplied as editable files formatted as a table in Microsoft Word or Excel.

To be added after the reference list.

Authors are responsible for obtaining permission for all copyright material, including tables, figures and images. Please provide licences with submission.

References

In text: All articles must be fully referenced

References must be numbered in order of first mention. They must be indicated in the text by a superscript number with the full list at the end of the article in numerical/chronological order.

Include the first three authors only, followed by et al., unless there are four authors, in which case list all four. Authors must include DOI and PubMed ID. (PubMed IDs can often be imported simply and quickly using a software such as EndNote which most institutions have access to.)

Examples: 

Journal article: Delpón E, Cordeiro JM, Núñez L, et al. Functional effects of KCNE3 mutation and its role in the development of Brugada syndrome. Circ Arrhythm Electrophysiol 2008;1:209–18. https://doi.org/10.1161/CIRCEP.107.748103; PMID: 19122847.

Book Chapter: Mansbach H. Sumatriptan: looking back and looking forward. In: Humphrey P, Ferari M, Olesen J (eds). The Triptans. New York: Oxford University Press, 2001;183–9.

Permissions

Authors are responsible for obtaining permission for all copyrighted material, including tables, figures and images. Permission is required irrespective of ownership. Permission proof is required at the time of submission. Papers cannot be accepted for publication until all necessary permissions are obtained.

Resources

When preparing your manuscript, we recommend you consult the following resources to improve the quality of your submission: 

1.6 Article Preparation: In Detail

Articles should be supplied in Microsoft Word, with all pages clearly numbered. The work should not be already submitted for consideration elsewhere nor have been previously published.

Title page: Should include the title of the article; author(s)’ full name, position and institution; an abstract and keywords; any relevant conflicts of interest; corresponding address; and article word count (excluding references).

Abstract:

Reviews, Expert Opinions and Case Reports: Unstructured, unreferenced abstract of no more than 160 words. Provides the context of the article. Should summarise the purpose, basic procedure, main findings and key conclusions.

Original Research: Structured abstract of no more than 250 words under the following sub-headings:

  • Background – include the specific study aims or hypothesis
  • Methods – include study design, setting, patients, interventions and main outcome measures
  • Results – give numerical data rather than vague statements that drug x produced a better response than drug y. Favour confidence intervals over p values, and give the numerical data on which any p value is based. Include absolute as well as relative risk numerical data
  • Conclusion – do not make any claims that are not supported by data in the paper
  • Trial Registration – if the trial has been registered, please include the NCT number of the relevant database number.

Keywords: Keywords capture the essence of your paper and help others to find your content when they are conducting a search on a particular topic. The below guidelines aim to ensure that the maximum number of people possible will be able to find your article:

  1. Write a list of keywords or keyphrases that you believe healthcare professionals would type into a search engine when trying to find content such as yours. Write down as many as possible, we suggest a minimum of seven.
  2. Group these words into logical themes.
  3. Write down semantic keywords that could be used as alternatives across these themes.
  4. Try to insert both keywords and the sematic keywords into the content, but only if the keywords can be inserted in a way that will be natural to both your writing and to the reader. The reader should always be the focus.
  5. Include some of these keywords in the title of your work: use one or two of the words that you believe are the most popular, while also being highly relevant to your content.
  6. If you have any questions about keywords while writing your work, we have a dedicated marketing department that can assist you; please ask.  

Article length: Each article type has its own word limit. Articles submitted with word counts exceeding the limit will either be returned for reduction by the author or be reduced in length by the editor. Please refer to the table above for guidance on word limits based on content type.

Layout:

Reviews, Expert Opinions and Case Reports: Use headings within the text to make it easier to read and understand. Subdivide the text into main sections with subheadings. Keep these short and succinct and similar in sense and style.

Original Research: Must include the following headed sections:

  • Introduction
  • Methods
    • Patient and Public Involvement statement (if relevant)
  • Results
  • Discussion
    • Study limitations

Introduction: Brief description of the background that led to the study (current results and conclusions should not be included). Clearly state the study specific aims or hypothesis.

Methods: Provide details of the study population and describe statistical methods with enough detail to enable the reader to judge its appropriateness for the study and to verify the reported results.

Patient and Public Involvement statement: When reporting patient and public involvement in research, please address the following, tailored as appropriate for the study design reported:

  • 1. Stage in the research process were patients/the public were involved and how
  • 2. How their priorities, experience, and preferences were used to develop and inform the research question(s) and outcome measures
  • 3. How they were involved in the design of this study
  • 4. How they were involved in the recruitment to and conduct of the study
  • 5. State if they were asked to assess the burden of the intervention and time required to participate in the research
  • 6. How/will they be involved in dissemination of the study results to participants and relevant wider patient communities (e.g. by choosing what information/results to share, when, and in what format)?

If patients were not involved please state this.

Results: Comment on validity and significance of results. Include subheadings to aid clarity of presentation within this and the previous section.

Use tables to summarise data when possible, rather than text. Where graphical displays of quantitative data are used, ensure that the message is easy to visualise and understand, and kept in context. Avoid graphical forms that distort the data or are prone to misinterpretation.

Discussion: Discuss what your findings show, why they are interesting and how they support or challenge existing studies in the area. Caveats to the study should be discussed.

Study limitations: Please include the limitations of your investigation at the end of the discussion section of your manuscript

Language: All articles should be written in UK English, free from jargon, and the writing should be clear and direct. All acronyms and abbreviations must be explained in full at first mention. We use UK spelling (unless the submission if for US Cardiology Review, which uses US spelling).

Figures: Tables, illustrations, screenshots and photographs – A maximum of five may be used. Anything above this number should be supplied as supplementary data. In addition, any Tables that require more than 2 pages, must be supplied as supplementary material. These are welcome where they add emphasis, clarity and/or interest to articles and should be clearly labelled with relevant captions. They must be referred to in the main text and numbered sequentially. All symbols and abbreviations used in figures must be defined.

Illustrations: Digital files must be saved as .tiff, .pdf or .jpeg format and be at least 300dpi. Original figures may be redrawn as necessary.

Videos: May be published in the online article with a still image of the video in the print file/PDF. Videos to be submitted in mp4 or avi format. Please ensure the video is accurately labelled. Any additional videos submitted but not included in the main article may appear as supplementary data.

Clinical Perspective: If applicable to the content type, include a Clinical Perspective section at the end of the article, summarising the clinical implications of your review in two to five bullet points.

Supplementary data: Supplementary material may be submitted to the journal if it is necessary to the integrity and excellence of the manuscript. It may take the form of figures, tables, datasets, videos, slide sets, formulas, podcasts etc. Supplementary material must be submitted at the time of manuscript submission as a separate file and will be published as a pdf file (unless in audio or video format).

Please note: Supplementary material will be subject to the same peer-review standards as the manuscript but will not be edited by the journal staff. Therefore, please take care to ensure that supplementary content is labelled and presented correctly, that grammar is corrected and that the journal style is followed throughout, especially in the references. Supplementary references must be cited in the main article and referenced at the end of the manuscript/acknowledgements.

1.7 Permissions

If a figure, table or illustration has been previously published, please ensure the original source is acknowledged as a figure legend and written permission from the copyright holder is sought. All figures/tables must have one of the below statements if they are not original:

If it is data taken from and no permissions are required – Data from: XXX et al. YEAR,RefXXX et al. YEAR,RefXXX et al. YEAR.Ref
If it is reproduced – Source: XXX et al. YEAR.Ref Reproduced with permission from PUBLISHER.
If it is adapted – Source: XXX et al. YEAR.Ref Adapted with permission from PUBLISHER.

Original images that are the authors own and that have not been published elsewhere, do not require permission. If applicable, please indicate this as a legend in your submission. If all images are original, please include a statement to this effect in the manuscript/at submission.

Our journals are open access. Please ensure that open access reuse permission is sought where possible. If it if not, please highlight this by adding ‘This content is not covered by the Creative Commons license of this publication. To reuse, please contact the rights holder.’

Authors are responsible for obtaining permission for all copyrighted material, including tables, figures and images. Permission is required irrespective of ownership. Permission proof is required at the time of submission. Papers cannot be accepted for publication until all necessary permissions are sought.

1.8 Declarations: Conflict of Interest and Intellectual Property

A conflict of interest exists when an opinion may be influenced or biased by a secondary interest such as financial gain. Conflicts of interest may occur from commercial or financial interests and/or personal relationships, beliefs and or rivalries such as research funding, consultancy services, serving on speakers’ bureaus, travel expenses, appearance fees, the receipt of share options, or direct employment by a commercial entity.

Our publications make it clear where any conflicts of interest occur and inform readers when research has been funded. All authors, peer reviewers, editors and editorial board members must declare any conflicts of interest pertaining to the article when submitting a manuscript. All sources of support for the work where a conflict exists will be publicised. Conversely, please state clearly should there be no conflicts of interest to declare.

Reviewers must declare any conflicts of interest before conducting a peer review of a manuscript. Reviewers should decline to review if a potential conflict of interest is present. Editorial staff employed by Radcliffe Group, editors-in-chief, guest editors and editorial board members, will not handle manuscripts where a potential conflict of interest or competing interest exists and will be excluded from the peer-review process.

Editorial members and guest editors may submit to the Journal and are not given any priority over other manuscript submissions. Articles authored by any in-house Editorial Board members will be treated with the same rigorous peer-review rules and handled avoiding any potential conflicts of interest. Where an author is a guest editor or editorial board member, this must be declared using one of the following statements in the submitted manuscript: [Author initials], is on the [insert journal name] editorial board; this did not influence peer review. For multiple editorial board members: [Author initials], is a/an [insert role] and [Author initials] is on the [insert journal name] editorial board; this did not influence peer review. [unless they have other COIs, in which case these shall be listed and added to the individual COIs]

The authors must complete the questions asked in our electronic submission system (Editorial Manager), which follows the ICMJE recommendations. These answers will be stored, and a disclosure statement will appear on every manuscript published within the journal based on your response. The purpose of this statement is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. For more information and to download a Form for Disclosure of Potential Conflicts of Interest, which can be submitted with your manuscript, please visit https://www.icmje.org/conflicts-of-interest.

Acknowledgements: The author(s) should acknowledge substantive contributions to the article, including receipt of financial assistance, materials and other resources.

Informed consent: Authors should include a statement in the manuscript that informed consent was obtained if experimentation with human subjects was conducted. The privacy rights of human subjects must always be observed. For more information please read: https://www.radcliffecardiology.com/privacy-statement

Human and animal rights: If the work involves the use of animal or human subjects, the author should ensure that the work described has been carried out following the Code of Ethics of the World Medical Association (Declaration of Helsinki) for research involving humans or the EU Directive 2010/63/EU for animal experiments and/or ARRIVE guidelines for animal research.

1.9 References

All articles must be fully referenced following the Vancouver referencing style. References must be numbered in order of the first mention and must not be used to promote self-interests.

In-text citations
In-text citations must be indicated in the text as superscript, without parentheses and should appear after punctuation at the end of a sentence with no space preceding. Use commas between numbers and en-dashes between ranges. List references by a number with the full list at the end of the article in numerical order.

Journal Articles
Journal abbreviations are used as per Medline. If there are more than three authors, list the first three followed by et al., unless there are four authors, in which case list all four. Details should be ordered as: Surname Initials. Article title. Journal name year;volume:page numbers. doi: [doi number]. PMID: [PMID number].

Example: Delpón E, Cordeiro JM, Núñez L, et al. Functional effects of KCNE3 mutation and its role in the development of Brugada syndrome. Circ Arrhythm Electrophysiol 2008;1:209–18. https://doi.org/10.1161/CIRCEP.107.748103; PMID: 19122847.

Book Chapters
Example: Mansbach H. Sumatriptan: looking back and looking forward. In: Humphrey P, Ferari M, Olesen J (eds). The Triptans. New York: Oxford University Press, 2001;183–9.

2.0 Peer Review Process

We operate a double-blind peer-review process. All peer reviews are conducted within the Editorial Manager platform.

On submission, items submitted to the journal are assessed by the Editor-in-Chief to assess their suitability for inclusion. Items that are deemed unsuitable, fail a technical check or that are deemed more suitable for another journal are returned at this stage.

The Review Editor, following consultation with the Editor-in-Chief, Section Editors and/or a member of the Editorial Board, sends the manuscript for peer review. All peer reviews are conducted independently, treated confidentially and are double-blinded. We require a minimum of two independent peer reviews but will seek a third review where there are conflicting reports. Original research manuscripts will always require an additonal review from a Statistical Editor.

The peer reviewers are selected on the basis of their expertise in the article subject matter and have no conflicts of interest. Reviewers should decline to review if a potential conflict of interest is present. Peer reviewers are not part of the editorial staff and operate independently from the article. Editorial staff employed by Radcliffe Group, editors-in-chief, guest editors and editorial board members, will not handle manuscripts where a potential conflict of interest or competing interest exists and will be excluded from the peer-review process.

Editorial members and guest editors may submit to the Journal and must declare this. Their status has no bearing on the editorial considerations given during the peer review process. Articles authored by any in-house Editorial Board members will be treated with the same rigorous peer-review rules and handled avoiding any potential conflicts of interest. Where an author is a guest editor or editorial board member, this must be declared using one of the following statements in the submitted manuscript: [Author initials], is on the [insert journal name] editorial board, which did not affect the peer-review process. For multiple editorial board members: [Author initials], is a/an [insert role] and [Author initials] is on the [insert journal name] editorial board, which did not affect the peer-review process. [unless they have other COIs, in which case these shall be listed and added to the individual COIs]

The peer-review feedback is used to critically assess the quality of the article, to assess its suitability for inclusion in the journal and to ensure its credibility of scientific information.

Following review, manuscripts are either accepted without modification, accepted pending modification, or may require further revision, in which case the manuscripts may be returned to the author(s) to incorporate required changes, or may be rejected outright. Not all articles that are revised are subsequently accepted. The Editor-in-Chief reserves the right to accept or reject any proposed amendments.

Once the authors have revised a manuscript in accordance with the reviewers’ comments, the manuscript is returned to the reviewers to ensure the revised version meets their quality expectations. Once approved, the manuscript is sent to the Editor-in-Chief for final approval prior to publication. We aim to complete the peer review process with the average time from submission to the first decision within 5 weeks and submission to a final decision within 9 weeks.

It is our aim to ensure authors are notified of any rejection or retraction as soon as possible. An editor can reject an article at any time before publication, including after acceptance if there are concerns over the work. In the event that a journal is no longer published, access to all articles will be available via alternative platforms, such as PubMed Central, ESCI or Scopus.

3.1 Proofs

All accepted manuscripts will be subject to editorial revisions for clarity, punctuation, syntax and conformity to house style.

Laid-out proofs will be sent to the corresponding author following the first stage of editing. Any requests for changes must be returned by the deadline given. Articles are considered final once an author approves the corrected proofs. Only minor changes can be made at the proofing stage; major changes will not be accepted.

4.1 Tips for Increasing Visibility and Impact

As the number of research articles being published each year continues to grow, it is important to maximise your articles' visibility and those published in journals that you are on the editorial board for. This is especially important for encouraging people to read and cite your articles.

 

Radcliffe Cardiology’s portfolio of journals which includes Arrhythmia & Electrophysiology Review, Cardiac Failure Review, European Cardiology Review, Interventional Cardiology Review and US Cardiology Review, are all published on a gold open access basis and therefore are freely available to readers, making them accessible and easy to share and promote. Here are some tips for encouraging citations to your articles and those published in your journals.

 

 

Tips for Authors

 

 

Before Publication

 

  1. Maximise search engine optimisation (SEO) by including keywords in your title and abstract.
  2. Add section/ subheadings with keywords to the different sections of your article.
  3. Don’t be afraid to repeat keywords or phrases, as this will increase the likelihood of your article being placed higher in search engine results – just ensure that your repetition is not excessive.
  4. Collaborating with co-authors and combining networks will increase the visibility, reach and potential citations to your article.
  5. Ensure your author name is accurate and consistent across articles, as this makes it easier for readers to find all of your published work. For common names to avoid any confusion, use a research identifier, such as an ORCID.
  6. Cite your previous articles in new articles that you are writing where they are relevant.

 

Following Publication

 

  1. Share a link to your article on social media (including Twitter, LinkedIn, Facebook, Academia.edu, ResearchGate, Mendeley) and on your institution profile page. Don't forget that when you post, or reply to posts, to use #'s and tag us @radcliffeCARDIO or @radcliffeVASCU and the authors/speakers of your content.
  2. Send a copy of your article colleagues.
  3. Add a copy of your article to your institutional repository.
  4. Network and attend key conferences and events and talk about your research.
  5. When presenting at conference and events, refer to any of your relevant previously published articles.

 

Tips for Editors and Board Members

 

  1. Promote the journal by including relevant journal articles on your reading lists if in a teaching role.
  2. Cite relevant journal articles in articles you are currently writing.
  3. When presenting at key conferences and events refer to relevant articles from the journal in your slides.
  4. Networking is key to building relationships and increasing journal awareness within the community. Not only will it attract submissions, readers and citations but it will also help with finding reviewers and potential editorial board members.
  5. Ensure that your review process is as efficient and effective as possible. Quick turnaround times will keep authors happy and increase the opportunity for the articles to make an impact.
  6. Publish regular special focus collections that address key/hot topics within the community and will generate interest.
4.2 Copyright, Permissions and Open Access

Articles published in our Journals are open access, which means the content is freely available, immediately upon publication, without charge, and allows users to read, download, copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly. The author retains all non-commercial rights for articles published under the Creative Commons Attribution Non-commercial CC-BY-NC 4.0 license. After your manuscript is accepted the corresponding author will be asked to sign a mandatory copyright transfer agreement (CTA) to grant us permission to publish the manuscript under these terms.

Radcliffe Medical Media retains all commercial rights for articles herein unless otherwise stated. Permission to reproduce an article or any of its contents for commercial purposes, either in full or in part, should be sought from the publication's Managing Editor.

Authors are responsible for obtaining permission for all copyright material, including tables, figures and images. Evidence will need to be provided for all permissions granted.

4.3 Author Fees

To support open access publication costs, Radcliffe Cardiology and Radcliffe Vascular charge an Article Publication Charge (APC) to authors upon acceptance of an unsolicited paper, as follows:
 

Content type

Fee

Indexed Journal (PubMed/Scopus/ESCI)

Non-indexed Journal

Article (Review/Original Research)

£1,050 | €1,200 | $1369

No fee

Case Report

£787 | €870 | $970

No fee

Editorial

No fee

No fee

Expert Opinion

£787 | €870 | $970

No fee

Letter

No fee

No fee

Meta-analysis

£787 | €870 | $970

No fee


Submissions from the UK will be subject to VAT. A VAT registration number should be supplied if applicable. If you are not registered for VAT, your invoice will still have VAT added.

After manuscript acceptance, the corresponding author will be contacted, and an invoice will be sent. Accepted articles will not be published until payment has been received.

4.4 APC Waivers and Discounts

A 100% waiver is applicable under the following circumstances:

  • For all content solicited by Radcliffe Cardiology/Radcliffe Vascular.
  • For all unsolicited content submitted to a non-indexed journal.
  • For all letters and editorials submitted to the journal.
  • For all content submitted by an editorial board member.
  • If the corresponding author is from a low-income country (as defined by the World Bank).

A 50% waiver is applicable under the following circumstances:

  • If the corresponding author is from a lower-middle-income country (as defined by the World Bank).

A 25% waiver is applicable under the following circumstances:

  • If the corresponding author submits a paper within 12 months of completing their most recent peer review for a Radcliffe journal.

Discretionary waivers may also be considered.

Radcliffe Cardiology/Radcliffe Vascular remains dedicated to helping researchers to disseminate scientific information globally and is working to partner with individual institutions to offer full or partial APC discounts. If you are an institution looking to partner with us, or think your institution should, then please contact the Publishing Director.

To ensure editorial integrity, the waiver process is not handled by the managing editors. Authors should submit a waiver request during the electronic submission process.

4.5 Misconduct and malpractice

We take reasonable steps to identify and prevent the publication of papers where misconduct has occurred. In no case shall we as the publisher or our editors encourage or knowingly allow such misconduct to take place to published and unpublished papers. 

Our journals use similarity checking software to detect unoriginal material and to avoid plagiarism. Where duplication is highlighted, the concerns will be raised with the author.

We do not permit the manipulation of research data through data falsification or data fabrication. Where data falsification or fabrication is suspected, the concerns will be raised with the author.

We reserve the right to reverse decisions to accept a submission where we believe our editorial policies have been infringed and papers suspected of misconduct will not be considered for publication. We reserve the right to inform the author’s co-authors and/or institution/regulatory body when such instances occur.

4.6 Errors, Omissions and Retractions

We take strive to ensure the academic integrity of our journals and to ensure that all content is reproduced correctly. However, we cannot guarantee the accuracy, adequacy or completeness of the information and cannot be held responsible for any errors or omissions, or for the results obtained from the use thereof. Occasionally circumstances may arise were an article is published that must later be retracted or removed. We commit to retract, correct and apologise for any inaccuracies or misleading statements with due prominence through errata which are issued as needed. Any errors should be reported to the journal’s Managing Editor. In all cases, our archives at The British Library and the Agency for Legal Deposit Libraries retain all versions.

4.7 Advertising

Advertising is not permitted to influence editorial decisions. Advertisements cannot be carried by the journal that juxtapose editorial content on the same product. Adverts may appear at the front and back of a journal (never within text). Misleading adverts may be refused. 

4.8 Complaints & Appeals

Any complaints should be first directed to the Editorial Office/Managing Editor of the Journal in writing. If they are the subject of the complaint, please raise this with the Publishing Director. We as the Publisher will aim to deal with any complaints or allegations of misconduct as appropriately and as swiftly as possible. If not resolved satisfactorily, any complaints can be passed to the overseeing body or ombudsmen where one exists. Complaints may be referred to COPES within six months if it cannot be resolved through the journal's complaints procedure and only if it pertains to procedural complaints rather than editorial content.

4.9 Reprints

Reprints of all published articles are available to authors, institutions and commercial organisations. Reprints are published as they appear in the journal unless a correction is to be added. Please contact Rob Barclay at rob.barclay@radcliffe-group.com

4.10 Data Sharing Policy

Radcliffe is committed to an open science landscape, removing barriers from the sharing of research and the underlying data. This facilitates openness, transparency and reproducibility of research. All Radcliffe journals are open access, and we encourage our authors to share their research data. Research data refers to the information gathered, reviewed, analysed, generated or created and can be presented in a variety of formats including numerical, descriptive, aural, or visual. We encourage Radcliffe authors to:

  1. share your research data in a relevant public data repository, where this does not violate the protection of human subjects or other valid subject privacy concerns.
  2. include a data availability statement (DAS) that links to your data. Where the data cannot be shared, you should confirm why it is not possible to share the data within this statement.
  3. cite the data in your research.

As all of our journals operate under a double-blind peer-review process, if sharing your data, you will need to use a repository that includes an option to preserve your anonymity.

Authors are encouraged to share their data but not required to. The decision to publish will not be affected by whether or not authors share their research data.

 

Data Repositories

We advise authors to speak to your institutional librarian, funder or colleagues for guidance on choosing a repository that is relevant to your discipline. Alternatively, some useful resources for searching for a suitable repository are FAIRsharing and re3data.org, which provide a list of certified data repositories. Some general repositories that are not subject-specific include:

 

Data Availability Statement

As per the ICMJE recommendations data sharing statements should include:

  1. whether individual de-identified participant data (including data dictionaries) will be shared (“undecided” is not an acceptable answer);
  2. what data, in particular, will be shared;
  3. whether additional, related documents will be available (e.g., study protocol, statistical analysis plan, etc.);
  4. when the data will become available and for how long;
  5. by what access criteria data will be shared (including with whom, for what types of analyses, and by what mechanism).

The table below provides some template statements that you may use or adapt. You can find further guidance on how to compose this statement on the ICMJE recommendations website.

Availability of data Template statement 
Data is openly available in a public repository (DOI provided) The data that support the findings of this study are openly available in [repository name e.g “figshare”] at http://doi.org/[doi], reference number [reference number].
Data openly available in a public repository (no DOI provided) The data that support the findings of this study are openly available in [repository name] at [URL], reference number [reference number].
Data derived from public domain resources The data that support the findings of this study are available in [repository name] at [URL/DOI], reference number [reference number]. These data were derived from the following resources available in the public domain: [list resources and URLs]
Embargo on data due to commercial restrictions The data that support the findings will be available in [repository name] at [URL / DOI link] following an embargo from the date of publication to allow for commercialization of research findings.
Data available on request due to privacy/ethical restrictions The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.
Data subject to third party restrictions The data that support the findings of this study are available from [third party]. Restrictions apply to the availability of these data, which were used under license for this study. Data are available [from the authors / at URL] with the permission of [third party].
Data available on request from the authors The data that support the findings of this study are available from the corresponding author upon reasonable request.
Data sharing not applicable – no new data generated Data sharing is not applicable to this article as no new data were created or analyzed in this study.
Author elects to not share data Research data are not shared.
Data available in article supplementary material The data that supports the findings of this study are available in the supplementary material of this article.
Data sharing not applicable – no new data generated, or the article describes entirely theoretical research Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

 

Data Citation

Radcliffe supports the Force 11 Data Citation Principles, as such all publicly available datasets must be fully referenced in the reference list with an accession number or unique identifier such as a digital object identifier (DOI) using the following format and in line with the Radcliffe reference style:

[dataset]* Authors, Year, Title, Publisher (repository or archive name), accession number/DOI * The [dataset] tag will help us identify and tag the correct citation, but this will be removed prior to publication.

 

We protect an individual's data and will not publish any patient data that might identify an individual without their written consent. For detailed information on our data sharing policy please click here.